$ISCO
International Stem Cell CORP

2022 Q1 Form 10-Q Financial Statement

#000156459022020039 Filed on May 13, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $2.020M $1.658M
YoY Change 21.83% -29.75%
Cost Of Revenue $725.0K $615.0K
YoY Change 17.89% -28.24%
Gross Profit $1.295M $1.043M
YoY Change 24.16% -30.61%
Gross Profit Margin 64.11% 62.91%
Selling, General & Admin $1.133M $1.395M
YoY Change -18.78% -15.71%
% of Gross Profit 87.49% 133.75%
Research & Development $137.0K $215.0K
YoY Change -36.28% -29.04%
% of Gross Profit 10.58% 20.61%
Depreciation & Amortization $56.00K $66.00K
YoY Change -15.15% 4.76%
% of Gross Profit 4.32% 6.33%
Operating Expenses $1.133M $1.395M
YoY Change -18.78% 360.4%
Operating Profit $25.00K -$567.0K
YoY Change -104.41% 24.62%
Interest Expense -$34.00K $32.00K
YoY Change -206.25% 14.29%
% of Operating Profit -136.0%
Other Income/Expense, Net $34.00K -$32.00K
YoY Change -206.25% -139.02%
Pretax Income -$9.000K -$599.0K
YoY Change -98.5% 60.59%
Income Tax
% Of Pretax Income
Net Earnings -$9.000K -$599.0K
YoY Change -98.5% 60.59%
Net Earnings / Revenue -0.45% -36.13%
Basic Earnings Per Share $0.00
Diluted Earnings Per Share -$1.124K -$79.45K
COMMON SHARES
Basic Shares Outstanding 8.004M 7.539M
Diluted Shares Outstanding 8.004M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $398.0K $1.117M
YoY Change -64.37% 57.77%
Cash & Equivalents $398.0K $1.117M
Short-Term Investments
Other Short-Term Assets $338.0K $437.0K
YoY Change -22.65% 0.69%
Inventory $1.322M $1.055M
Prepaid Expenses
Receivables $902.0K $437.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.960M $3.046M
YoY Change -2.82% -9.88%
LONG-TERM ASSETS
Property, Plant & Equipment $348.0K $1.297M
YoY Change -73.17% 105.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $425.0K $434.0K
YoY Change -2.07% -3.13%
Total Long-Term Assets $2.541M $2.973M
YoY Change -14.53% -14.96%
TOTAL ASSETS
Total Short-Term Assets $2.960M $3.046M
Total Long-Term Assets $2.541M $2.973M
Total Assets $5.501M $6.019M
YoY Change -8.61% -12.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $635.0K $512.0K
YoY Change 24.02% -4.12%
Accrued Expenses $701.0K $888.0K
YoY Change -21.06% 23.68%
Deferred Revenue
YoY Change
Short-Term Debt $3.225M $2.852M
YoY Change 13.08% 19.08%
Long-Term Debt Due $219.0K
YoY Change
Total Short-Term Liabilities $4.811M $4.721M
YoY Change 1.91% 12.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $915.0K
YoY Change -100.0%
Other Long-Term Liabilities $896.0K $781.0K
YoY Change 14.72% -35.67%
Total Long-Term Liabilities $896.0K $1.696M
YoY Change -47.17% 39.7%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.811M $4.721M
Total Long-Term Liabilities $896.0K $1.696M
Total Liabilities $5.707M $6.417M
YoY Change -11.06% 18.42%
SHAREHOLDERS EQUITY
Retained Earnings -$110.0M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$4.506M -$4.698M
YoY Change
Total Liabilities & Shareholders Equity $5.501M $6.019M
YoY Change -8.61% -12.46%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$9.000K -$599.0K
YoY Change -98.5% 60.59%
Depreciation, Depletion And Amortization $56.00K $66.00K
YoY Change -15.15% 4.76%
Cash From Operating Activities -$23.00K -$394.0K
YoY Change -94.16% -248.68%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$2.000K
YoY Change -100.0% -166.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$2.000K
YoY Change -100.0% -95.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 250.0K 824.0K
YoY Change -69.66%
NET CHANGE
Cash From Operating Activities -23.00K -394.0K
Cash From Investing Activities 0.000 -2.000K
Cash From Financing Activities 250.0K 824.0K
Net Change In Cash 250.0K 428.0K
YoY Change -41.59% 91.07%
FREE CASH FLOW
Cash From Operating Activities -$23.00K -$394.0K
Capital Expenditures $0.00 -$2.000K
Free Cash Flow -$23.00K -$392.0K
YoY Change -94.13% -249.62%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q2 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P2Y
CY2021Q1 isco Paycheck Protection Program Loan Maturity Period
PaycheckProtectionProgramLoanMaturityPeriod
P5Y
CY2021Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2022Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2021Q1 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2021-01-31#ProductMember
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
832000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
2225000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
25000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-567000
CY2022Q1 isco Interest Expense Related Party Including Other Miscellaneous
InterestExpenseRelatedPartyIncludingOtherMiscellaneous
34000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1048000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1995000
CY2021Q1 us-gaap Cost Of Revenue
CostOfRevenue
615000
CY2022Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
301000
CY2021Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
347000
CY2021Q1 isco Interest Expense Related Party Including Other Miscellaneous
InterestExpenseRelatedPartyIncludingOtherMiscellaneous
32000
CY2022Q1 us-gaap Other Expenses
OtherExpenses
34000
CY2021Q1 us-gaap Other Expenses
OtherExpenses
32000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
8004000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-599000
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.00
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7539000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-4588000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
91000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-599000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-599000
CY2021Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
66000
CY2022Q1 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
33000
CY2021Q1 isco Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
69000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
234000
CY2021Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
27000
CY2021Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
34000
CY2021Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
151000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
263000
CY2021Q1 us-gaap Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
-13000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
152000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
174000
CY2021Q1 isco Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-82000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-394000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2000
CY2021Q1 isco Proceeds From Paycheck Protection Program Loan Amount
ProceedsFromPaycheckProtectionProgramLoanAmount
474000
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
250000
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
350000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
250000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110000000.0
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, and the fair value of stock option grants using the Black-Scholes option valuation model.  By their nature, estimates are subject to an inherent degree of uncertainty and actual results could differ from these estimates.</p>
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P15Y
CY2022Q1 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the biomedical market (LCT) and anti-aging market (LSC). The biomedical market sells primary human cell research products with two product categories, cells and media, which are sold both domestically and internationally. The biomedical market also offers performance of quality control (QC) testing services. No revenue from services was earned during the three months ended March 31, 2022 and 2021. Prior to January 1, 2022, the anti-aging market sold a line of skincare products through two sales channels: ecommerce and professional. The ecommerce channel sold directly to customers through online orders, while professional sales were primarily to spas, salons, and other skincare providers. As of January 1, 2022, the anti-aging market sells products solely through the ecommerce channel. As such, there was no revenue earned pertaining to professional channel skin care during the three months ended March 31, 2022.
CY2022Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2022Q1 isco Number Of Products Categories
NumberOfProductsCategories
2
CY2022Q1 isco Number Of Sales Channels
NumberOfSalesChannels
2
CY2022Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
902000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
844000
CY2022Q1 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2022Q1 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2021Q4 isco Financial Assets Fair Value Disclosure
FinancialAssetsFairValueDisclosure
0
CY2021Q4 us-gaap Financial Liabilities Fair Value Disclosure
FinancialLiabilitiesFairValueDisclosure
0
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11449057
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10309277
CY2022Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Customer Concentrations</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the three months ended March 31, 2022 and 2021, one customer accounted for approximately 45% and 40%, respectively, of consolidated revenues. As of March 31, 2022 and December 31, 2021, the customer accounted for approximately 51% and 62%, respectively, of accounts receivable, net. No other single customer accounted for more than 10% of revenues for the periods then ended for any segment.</p>
CY2022Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
645000
CY2021Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
592000
CY2022Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
603000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
507000
CY2022Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1051000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
983000
CY2022Q1 us-gaap Inventory Gross
InventoryGross
2299000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
2082000
CY2022Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
587000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
526000
CY2022Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1712000
CY2021Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1556000
CY2022Q1 us-gaap Inventory Net
InventoryNet
1322000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1184000
CY2022Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
390000
CY2021Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
372000
CY2022Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1712000
CY2021Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1556000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2508000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2507000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2160000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2123000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
348000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
384000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
37000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
42000
CY2021Q4 us-gaap Finite Lived Patents Gross
FiniteLivedPatentsGross
1277000
CY2022Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
858000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
874000
CY2022Q1 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2021Q4 isco Indefinite Life Logos And Trademarks
IndefiniteLifeLogosAndTrademarks
75000
CY2022Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
933000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
949000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
19000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
24000
CY2020Q2 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
654000
CY2020Q2 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2021Q1 isco Cares Act Of2020 Aid Amount
CARESActOf2020AidAmount
474000
CY2021Q1 isco Paycheck Protection Program Loan Interest Rate
PaycheckProtectionProgramLoanInterestRate
0.01
CY2022Q1 isco Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
0
CY2021Q4 isco Paycheck Protection Program Loan
PaycheckProtectionProgramLoan
0
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2021 us-gaap Dividends Preferred Stock
DividendsPreferredStock
0
CY2022Q1 us-gaap Preferred Stock Convertible Conversion Ratio
PreferredStockConvertibleConversionRatio
1
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
91000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
234000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
249000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y10D
CY2021Q4 isco Finance Leases
FinanceLeases
0
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
15610914
CY2021Q4 isco Lease Costs Incurred Percentage
LeaseCostsIncurredPercentage
0.40
CY2022Q1 isco Number Of Operating Leases
NumberOfOperatingLeases
3
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
11000
CY2021Q4 isco Percentage Of Increase Rent Per Annum Over Lease Term
PercentageOfIncreaseRentPerAnnumOverLeaseTerm
0.035
CY2021Q4 isco Percentage Of Base Rent Abated
PercentageOfBaseRentAbated
0.50
CY2021Q4 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2026-12-31
CY2021Q4 us-gaap Operating Lease Expense
OperatingLeaseExpense
4000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
73000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
118000
CY2022Q1 isco Finance Leases
FinanceLeases
0
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
242000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
338000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
349000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
360000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
119000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1408000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
316000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1092000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
196000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
896000
CY2022Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2022Q1 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2020000
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1658000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
1995000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
2225000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
25000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-567000

Files In Submission

Name View Source Status
0001564590-22-020039-index-headers.html Edgar Link pending
0001564590-22-020039-index.html Edgar Link pending
0001564590-22-020039.txt Edgar Link pending
0001564590-22-020039-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isco-10q_20220331.htm Edgar Link pending
isco-10q_20220331_htm.xml Edgar Link completed
isco-20220331.xsd Edgar Link pending
isco-20220331_cal.xml Edgar Link unprocessable
isco-20220331_def.xml Edgar Link unprocessable
isco-20220331_lab.xml Edgar Link unprocessable
isco-20220331_pre.xml Edgar Link unprocessable
isco-ex311_9.htm Edgar Link pending
isco-ex312_8.htm Edgar Link pending
isco-ex321_7.htm Edgar Link pending
isco-ex322_6.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending